

Pharma, MedTech and Digital Health Innovation Pipeline | October 2026

THERAPEUTIC PROGRAMS

Disease area/program name	Indication/product	Modality	Mechanism of Action	Discovery	Hit to lead	Lead Optimisation	Pre-clinical	Clinical	Sales
Oncology									
GARDASIL*	Cervical cancer	Vaccine	HPV-VLPs	●	●	●	●	●	●
* QEDDI TRPV6 inhibitor	Prostate cancer	Small molecule	Novel TRPV6 ion channel inhibitor	●	●	●	●		
* QEDDI Immuno-dermatology	Squamous cell carcinomas in organ transplant recipients (OTRs)	Small molecule	Topical immune cell rescue for OTRs on immune-suppression	●	●	●	●		
ROR1 antibody for ADC / radiotheranostics	Solid tumours	mAb	anti-ROR1 antibody for targeted cancer therapy	●	●	●	●		
Pain									
Nav 1.1/1.7 Inhibitor	Visceral Pain (Irritable Bowel Syndrome, Endometriosis)	Peptide	Dual inhibitor of Nav1.1 and Nav1.7	●	●	●			
KOPr targeting analgesics	Acute pain	Peptide	Peripherally-restricted peptide agonist for kappa-opioid receptor (KOR)	●	●				
Atypical safe opioid	Painful diabetic neuropathy, post-operative pain	Small molecule	Opioid receptor (MOP) agonist	●	●				
ASIC1b inhibitors	Chronic pain	Peptide	Selective all-d macrocycle ASIC1b inhibitors	●					
Inflammation and Autoimmune									
Inflazome acquired by Roche	Inflammation	Small molecule	Inflammasome NLRP3 inhibitor	●	●	●	●	●	
Tolerising T1D specific liposome immunotherapy	Type 1 diabetes	Lipid nanoparticle	Antigen specific immune tolerance induction	●	●	●	●		
Heterotrophic ossification prophylaxis	Musculoskeletal and trauma	Small molecule	Suppression of key inflammatory drivers	●	●	●	●		
Tolerising RA specific liposome immunotherapy	Rheumatoid arthritis	Lipid nanoparticle	Antigen specific immune tolerance induction	●	●	●			
HPGD2 inhibitor	Asthma, atopic dermatitis and Duchenne muscular dystrophy	Small molecule	HPGD2 synthase inhibitor	●	●	●			
Oral C5aR1 inhibitors	Peripheral inflammatory and autoimmune diseases	Peptide	Oral, non-competitive pseudo irreversible orthosteric antagonists of C5aR1	●	●	●			
Class IIa HDAC inhibitor	Inflammatory diseases including asthma and rheumatoid arthritis	Small molecule	Class IIa selective HDAC inhibitor	●	●				
C5aR1 inhibitors	Neuroinflammation and neurodegenerative diseases	Peptide	Orally available, peptide antagonists designed to suppress C5aR1-driven neuroinflammation	●	●				
C3aR modulators	Inflammatory lung diseases including asthma	Small molecule	C3a receptor antagonists	●	●				
* QEDDI Caspase-1 inhibitor	Inflammatory disorders	Small molecule	Novel allosteric Caspase-1 inhibitors	●	●				
* QEDDI NLRP1 inhibitor	Epithelial inflammatory diseases	Small molecule	First-in-class NLRP1 inflammasome inhibitors	●	●				
Macrophage driven inflammation	Inflammation incl. lupus and chronic granulomatous disease	RNA nanoparticle	Macrophage targeted mRNA	●	●				
CNS									
NuNerve	Amyotrophic lateral sclerosis and spinal cord injury	Biologic	EphA4 antagonist	●	●	●	●	●	
Infensa Biosciences	Stroke neuroprotection and cardiac myoprotection	Peptide	Selective ASIC1a inhibitor	●	●	●	●	●	
Anti-Tau antibody	Alzheimer's disease, neurodegeneration	Antibody	Epitope targeting 6 pathogenic isoforms of Tau protein	●	●	●			
Infectious Diseases									
Vicebio acquired by Sanofi	Multivalent respiratory virus vaccines	Vaccine	Hyper-stabilised viral pre-fusion protein vaccine platform	●	●	●	●	●	
Therapeutic Nipah virus nanobody	Nipah virus, Hendra virus	Single domain antibody	Anti-NiV neutralising nanobody	●	●				
Novel chimeric flavivirus vaccine platform	Dengue, Zika, Yellow Fever, West Nile and other flaviviruses	Vaccine	Chimeric flavivirus antigen with insect-specific flavivirus	●	●				
Antimicrobial defence in people with cystic fibrosis	Cystic fibrosis	mRNA therapeutic	Reinstatement of macrophage zinc toxicity response	●					
Malaria T-Cell Vaccine for sterile immunity	Malaria	Vaccine	T cell-based vaccine for sterile cross-species immunity	●					
Other									
First-in-class troponin modulator for heart failure	Heart failure with preserved ejection fraction (HFpEF) expansion potential across cardiac and skeletal disorders	Peptide	Troponin modulator with pure lusitropic mechanism of action	●	●				
AP-1 inhibitors	Age related diseases	Synthetic proteins	Epigenetic modulation	●					
* QEDDI TRPC3 inhibitors	Heart failure with preserved ejection fraction (HFpEF)	Small molecule	Novel TRPC3 ion channel inhibitor	●	●				

* The Queensland Emory Drug Discovery Initiative (QEDDI) is UniQuest's small molecule drug discovery and development group dedicated to translating academic biomedical research into new medicines. For more information, visit qeddi.com.au

● Already partnered

● Asset available for partnering

Pharma, MedTech and Digital Health Innovation Pipeline | October 2026

	Program Name	Indication/product	Modality	Mechanism of Action	Discovery	Pre-clinical	Clinical	Sales
REGENERATIVE MEDICINE	Regenerative Medicine, Cell and Gene Therapies							
	Kidney tissue from iPSCs	Kidney cells and organoids	Cell therapy	Stem cells	●	●		
	HA-PPS MSC differentiation to cartilage	Knee meniscus and spinal disc repair	Hydrogel/scaffold	Differentiation factor	●			
	ASIC1a knockout iPSC derived cardiomyocyte cell line	Improved myocyte engraftment (tolerance to acidosis & ischemia)	Cell therapy	Stem cells	●			
TOOLS AND ENABLING TECHNOLOGIES					POC validated	Prototype	Lead product	Sales
	Research and Development Tools							
	Automated Topology Builder (ATB)	Software to improve molecular modeling and molecular dynamic calculations of small molecules			●	●	●	●
	Growth hormone assay	<i>In vitro</i> bioassay (incl. potency) for growth hormone and analogues			●	●	●	
	Transcriptional Regulatory Inference Analysis from Gene Expression (TRIAGE)	A computational toolkit to analyse regulatory elements in both bulk and single-cell RNA sequencing (RNA-seq) datasets			●	●	●	
	mRNA capping quantification	Quantification of 5' caps on mRNA vaccines in a single assay			●			
	Quantification of interactions with Lipoproteins	Rapid screening assessment of lipoprotein binding			●			
	NASTIC	Single-molecule live-cell imaging platform			●	●	●	
	Enabling Technologies							
	DISC-Seq: Divisional Indexing Single-Cell-Sequencing	Enables tracking of cell generation using existing RNAseq workflows			●			
	CasPER Gene Editing	Next-generation gene editing platform for genomic insertions			●			
	Cell free mRNA manufacture	Cell-free manufacture of mRNA with 5'cap and polyA tail without endotoxin and bacterial contamination			●			
	Recombinant protein production booster	Expression platform to boost recombinant production of desired protein, peptide or small molecule without specialised culture conditions			●			
	Organoid Technologies							
MEDTECH & DIGITAL HEALTH	Follicular skin organoids	Method of producing functional follicular skin organoids from human iPSCs			●	●		
	Vascularised human skin organoids	Adult iPSC derived vascularised skin organoids with high physiological relevance			●	●		
	Endometriosis organoids	Endometriosis patient-derived micro-organoid spheres for precision medicine and drug screening			●			
	Biomedical Devices and Diagnostic Technologies							
	Impedimed	Lymphoedema bioimpedance			●	●	●	●
	Q-Sera	Universal blood collection pathology tubes that rapidly produce high quality serum			●	●	●	●
	Scanning ultrasound	Scanning ultrasound for treating Alzheimer's Disease			●	●		
	INOVIQ	Exosome-based ovarian cancer test			●	●		
	ResApp Health	Mobile health for respiratory disease diagnosis			●	●	●	●
	Ketamine response algorithm	Clinical decision support tool to predict remission to ketamine in PTSD/treatment-resistant depression patients			●			
	Diagnostic and prognostic for Multiple Sclerosis	Proof of Principle			●			
	Liver viability biomarkers for liver transplants	Point-of-Care real time liver viability assessment for liver transplants undergoing Normothermic Machine Perfusion (NMP)			●			
	Diagnostic and prognostic signatures for sepsis	High confidence gene signatures to identify bacterial sepsis, and development of organ dysfunction			●			
	Gamma-Entrained Stroke Recovery	Non-invasive audiovisual neuromodulation for stroke			●			
	Vaccine and Drug Delivery Platforms							
	Vaxxas	Needle-free vaccine delivery using high-density micro-array patch (HD-MAP)			●	●	●	
	ProGel	Oral and gut stable encapsulation of API for release in small intestine			●	●		
	Nanocapsules	Encapsulated emulsion droplets for sustained or burst release and ability to coat microbes			●			
	Permeation enhancing nanoparticles	Platform for the delivery of biologics across intestinal, mucosal and/or blood brain barriers			●			

● Asset available for partnering
● Already partnered

